Search clinical trials for: optimized background regimen

Total 4307 results

National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

Tuberculosis | Rifampicin Resistant Tuberculosis

Brazil, India, South Africa, Tanzania, Thailand
United BioPharma

Not yet recruiting

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

HIV-1 Infection
United BioPharma

Not yet recruiting

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

HIV-1 Infection
National Institute of Allergy and Infectious Diseases...
Otsuka Pharmaceutical Development & Commercialization, Inc.

Recruiting

Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

HIV Infections | Tuberculosis

Tanzania, India, South Africa, Botswana
Gilead Sciences

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

HIV-1-infection

United States, Spain, France, Taiwan, Japan, Thailand, Dominican Republic, Germany, Canada, Italy, South Africa
Boston University
National Institute of Allergy and Infectious Diseases (NIAID); Centers for... and other collaborators

Completed

Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (Opti-Q)

Tuberculosis, Multidrug-Resistant

South Africa, Peru
CytoDyn, Inc.

Completed

Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 (PRO140)

HIV

United States, Puerto Rico
ViiV Healthcare
Pfizer

Completed

Prospective Observational Epidemiologic Study of Maraviroc's Safety (POEM)

Human Immunodeficiency Virus

United States, Canada, Spain, Belgium, France, United Kingdom, Italy, Brazil, Puerto Rico, Germany, Greece
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

Tuberculosis, Pulmonary | Extensively Drug-Resistant Tuberculosis | Tuberculosis, Multidrug Resistant

Korea, Republic of, China, United States, Egypt, Estonia, Japan, Latvia, Peru, Philippines
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis

Tuberculosis

Latvia, Lithuania
Merck Sharp & Dohme LLC

Completed

Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672) (VICTOR-E1)

HIV Infections
TaiMed Biologics Inc.
Westat

Completed

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

HIV

United States, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...

Completed

A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)

Multidrug Resistant Tuberculosis

Philippines, South Africa
TaiMed Biologics Inc.

Completed

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

HIV

United States, Taiwan, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...

Completed

Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis

Pediatric | Multidrug Resistant Tuberculosis

Philippines, South Africa
Hoffmann-La Roche

Completed

Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

HIV Infections

France
ViiV Healthcare
GlaxoSmithKline

Completed

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

Infection, Human Immunodeficiency Virus

United States, France, Spain, Canada, Italy
Gilead Sciences

Completed

Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy

HIV Infections

Brazil, Panama
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Boehringer Ingelheim

Terminated

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

HIV Infections

United States, Argentina, Brazil, Canada, Germany, Italy, Spain
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

HIV

United States, France, Argentina, Chile, Mexico, Costa Rica, Panama, Brazil, Puerto Rico, Thailand
TaiMed Biologics Inc.

Completed

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 (TMB-202)

HIV

Puerto Rico, United States
Bamrasnaradura Infectious Diseases Institute
Department of Disease Control, Thailand

Completed

Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure (BIDI-MONO)

HIV | AIDS | Treatment Failure | Lopinavir

Thailand
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

HIV
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC; Janssen-Cilag Tibotec

Completed

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)

HIV Infections

France
Myrexis Inc.

Terminated

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

HIV Infections

Canada, United States
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
National Institute of Allergy and Infectious Diseases...

Recruiting

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

Multi-Drug Resistant Hiv-1 Infection | HIV-1 Infection

United States
Sao Thai Duong Joint Stock Company
Vietstar Biomedical Research

Recruiting

Safety and Efficacy of Softgel KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)

COVID-19

Vietnam
Sao Thai Duong Joint Stock Company
Big Leap Clinical Research Joint Stock Company

Not yet recruiting

Efficacy of KOVIR Capsule in the Combination Regimen With Background Treatment in COVID-19 Patients

COVID-19

Vietnam
Peking Union Medical College Hospital
The First Affiliated Hospital of Anhui Medical University; Peking University... and other collaborators

Recruiting

Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide

Multiple Myeloma

China
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy; California Institute for Regenerative... and other collaborators

Recruiting

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast Cancer | Neuroendocrine Tumors | Lung Adenocarcinoma | Metastatic Melanoma | Head and Neck Squamous Cell Carcinoma | Refractory Malignant Solid Neoplasm | Thyroid Cancer | Pheochromocytoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Pathologic Stage IIIC Cutaneous Melanoma... and other conditions

United States
ANRS, Emerging Infectious Diseases

Recruiting

Evaluation of Third-line cART Regimen in Cambodia (3DICAM)

HIV/AIDS

Cambodia
Janssen Research & Development, LLC

Recruiting

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB

Multidrug-Resistant Tuberculosis

Mozambique, Philippines, Russian Federation, South Africa, Uganda, Ukraine
Janssen Research & Development, LLC

Completed

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

HIV

Italy, Thailand, Spain, Uganda, Portugal, South Africa
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
Sao Thai Duong Joint Stock Company
Big Leap Clinical Research Joint Stock Company

Completed

Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR) (KOVIR)

COVID-19

Vietnam
Lund University
Baxter Healthcare Corporation; Universidad de Córdoba

Completed

Optimized vs. Standard Automated Peritoneal Dialysis Regimens Study (OptiStAR)

End Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic Dialysis

Argentina
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Tuberculosis, Multidrug-Resistant

Japan
Gilead Sciences

Completed

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

HIV Infections | Acquired Immunodeficiency Syndrome | HIV-1

United States, Canada
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Completed

Renal Denervation in Hypertension (DENER-HTN)

Hypertension, Resistant to Conventional Therapy | Renal Denervation

France
Gilead Sciences

Terminated

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

HIV Infections | Acquired Immune Deficiency Syndrome (AIDS)

United States, Thailand, Spain, Uganda, South Africa, Italy
Community Research Initiative of New England

Completed

BRAVO: Background Regimen of Raltegravir on Virologic Outcome (BRAVO)

HIV Infections

United States
CytoDyn, Inc.

Withdrawn

A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

HIV

United States
Hoffmann-La Roche
Trimeris

Completed

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

HIV Infections

United States, Canada, Puerto Rico
Pfizer

Completed

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Gilead Sciences

Completed

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

HIV Infection

Canada, Germany, United States, Spain, France, Australia, Puerto Rico, Italy, Belgium, Mexico, Switzerland, Portugal, Netherlands, United Kingdom
Merck Sharp & Dohme LLC

Approved for marketing

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

HIV Infections
Centre hospitalier de l'Université de Montréal...

Completed

Optimized Heparin Regimen in Vascular Surgery

Peripheral Revascularisation

Canada
Janssen Infectious Diseases BVBA

Withdrawn

A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis

Multi-drug Resistant Tuberculosis

China, Ukraine, Taiwan, Korea, Republic of, Peru, Brazil, Estonia, Latvia, Philippines, Russian Federation, South Africa, Thailand, Turkey, Georgia, Mexico, Cambodia, Ethiopia

3

Subscribe